Terns Pharmaceuticals, Inc. (TERN, Financial) experienced a significant stock price decline of 5.08%, trading at $5.61 per share. The trading volume reached 553,182 shares with a turnover rate of 0.65% and a price fluctuation of 4.83%. Recent financial reports indicate zero revenue, a net loss of $21.95 million, earnings per share of -$0.28, a gross loss of $206,000, and a price-to-earnings ratio of -4.77.
Among the nine institutions rating the stock, 78% recommend buying, while 22% suggest holding, with no sell recommendations. The biotechnology sector, where Terns Pharmaceuticals operates, saw an overall increase of 0.33%. Notably, Forte Biosciences, Inc. and Exicure, Inc. showed significant gains and high turnover rates of 1881.11% and 1007.48%, respectively. Klotho Neurosciences Inc and Forte Biosciences, Inc. also exhibited substantial price fluctuations.
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing small molecule single-agent and combination therapy candidates for non-alcoholic steatohepatitis (NASH) and other chronic liver diseases.
